Coronavirus SARS-CoV-2 (2019-nCoV) Antigen Reagent

ICTV (International Committee on Taxonomy of Viruses) announced “severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)” as the name of the new virus on 11 February 2020. This name was chosen because the virus is genetically related to the coronavirus responsible for the SARS outbreak in 2003. WHO officially announced “COVID-19” as the name of this new disease on 11 February 2020, following guidelines previously developed with the World Organisation for Animal Health (OIE) and the Food and Agriculture Organization of the United Nations (FAO).

The coronavirus genome encodes four or five structural proteins. They are a spike protein [S], a small envelope protein [E], a membrane protein [M], a nucleocapsid protein [N], and sometimes a hemagglutinin-esterase protein [HE]. 

The spike protein is the major surface membrane protein of coronavirus, which is composed of two subunits, S1 and S2. S1 can function as a receptor-binding domain (RBD) while S2 contains the basic elements required for the membrane fusion process.

The Spike protein is responsible for binding to the host cell receptor and membrane fusion. It plays key parts in neutralizing host antibodies and vaccine design. The interaction between Spike protein of SARS-CoV-2 and RBD-human ACE2 interfaces to enhance the viral binding to human ACE2 and plays a critical role in the infection of respiratory epithelial cells.

The nucleocapsid protein is one of the most abundant structural proteins during SARS-CoV infection and is highly phosphorylated. During the assembly of the virion, the N protein binds to the viral RNA and causes the formation of a spiral nucleocapsid. Nucleocapsid protein is a highly immunogenic phosphoprotein, which is involved in viral genome replication and regulating cell signaling pathways. Due to the sequence conservation and strong immunogenicity of N protein, N protein is often used as a diagnostic tool for coronavirus.

In order to better support the development and basic research of coronavirus diagnostic reagents, vaccines and therapeutic drugs, our professional R&D team has developed and produced a series of coronavirus Spike target to antigen and N protein related reagents including recombinant proteins, antibodies, antigen protein detection kits, genes, etc.

Angiotensin-converting enzyme 2 (ACE2)

Angiotensin-converting enzyme 2 (ACE2) is a membrane receptor expressed on the surface of airway epithelial cells. In the early 21^st century, scientists began to conduct in-depth research on ACE2. ACE2 has been shown to be the host cell receptor for two human coronaviruses, SARS-COV and HCoV-NL63. And it can interact with the coronavirus Spike protein. This interaction which mediated by the RBD domain of the Spike protein is considered to be a key step in membrane fusion between the virus and the cell. Recently, ACE2 has once again attracted great attention for it is shown to be a host cell receptor for a newly discovered lethal coronavirus SARS-CoV-2 (2019-nCoV). This finding suggests that blocking the interaction between S protein and ACE2 is an effective treatment for coronavirus infection.

Theoretically, both SARS-CoV-2 virus and receptor ACE2 can be used as therapeutic targets for effective intervention against viral infection. Soluble Spike proteins or blocking antibodies can be used to block ACE2 to prevent viral infection. Similarly, soluble ACE2-Fc fusion protein can be used to block S1 protein on virions to achieve the same effect.

In addition to its important role in mediating virus entry into host cells, ACE2 is very likely to play a pivotal role in the pathogenesis of respiratory diseases. ACE2 is an important regulatory factor of the renin-angiotensin system (RAS). ACE2 can negatively regulates its activity by converting angiotensin II into the product angiotensin 1-7. Dysregulation of ACE2 can be observed in lung lesions caused by RSV and avian influenza (H5N1) infection. And it is also shown that the use of ACE2-Fc fusion protein can reduce symptoms in animal models.

We have developed and produced a series of ACE2 related proteins and antibody reagents. Among them, ACE2 related protein reagents have a strong binding affinity to the Spike Protein and enzyme.

Below is the product list:

Coronavirus Protein Detection Kit

In order to control the COVID-19 outbreak in the world, scientists have invested amount of research work in the development of SARS-CoV-2 vaccines and related therapeutic drugs. So it is imminent for scientists to find a method that can quickly and quantitatively detect viral antigens.

SARS-CoV-2 Antigen protein reagent :

SARS-CoV-2 Antigen reagent:

Why Leading Biology?

At Leading Biology, we custom protein purification design for every single protein to ensure the production and recovery rate as high as possible.

Working with us, you will get stability, and it means a reliable partner to help streamline your R&D process.

Working with us, you will get the guaranteed service to accommodate your requirements.

· Innovative configurations of chromatography columns custom-tailored to each protein

· Vigorous quality control system to ensure the required quality and reproducibility

· Production capacity of up to tens of grams

· Flexible scale-up protein production

· Competitive price with fast turnaround time

Contact Information

Please obtain a quote before ordering, and refer to the quote number when you place an order.

Orders are typically confirmed within 12 hours.

Have a Question? Email us info@leadingbiology.com

Order Products: Order Related Products

By Phone: 1-661-524(LBI)-0262 (USA)